Copyright
©2014 Baishideng Publishing Group Co.
World J Diabetes. Feb 15, 2014; 5(1): 76-83
Published online Feb 15, 2014. doi: 10.4239/wjd.v5.i1.76
Published online Feb 15, 2014. doi: 10.4239/wjd.v5.i1.76
Treatment | n (%) |
Antidiabetic | 740 (92.9) |
Insulin | 145 (19.6) |
Biguanide (metformin) | 519 (70.1) |
Sulfonylurea | 343 (46.4) |
Glitazone | 142 (19.2) |
Others | 104 (14.1) |
Lipid-lowering | 553 (69.4) |
Statin | 517 (93.5) |
Ezetimibe | 53 (9.6) |
Fibrate | 17 (3.1) |
Others | 43 (7.8) |
Antihypertensive | 591 (96.11) |
ARBs | 330 (55.8) |
ACEi | 202 (34.2) |
CCBs | 242 (40.9) |
Beta-blockers | 179 (30.3) |
Alpha-blockers | 13 (2.2) |
Diuretics | 220 (37.2) |
Others | 19 (3.2) |
Anti-obesity | 40 (5.0) |
Aspirin | 298 (37.4) |
- Citation: Kostapanos MS, Tsimihodimos V, Elisaf MS, Tzouvelekis E, Nikas N. Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece. World J Diabetes 2014; 5(1): 76-83
- URL: https://www.wjgnet.com/1948-9358/full/v5/i1/76.htm
- DOI: https://dx.doi.org/10.4239/wjd.v5.i1.76